Empatica’s EmbracePlus, the only medically certified smartwatch, received the European CE approval as a Class IIa medical device.
The EmbracePlus is a medical-grade smartwatch that helps with continuous monitoring of numerous physiological signals that include the pulse rate, pulse rate variability, blood oxygenation, respiratory rate, skin temperature, electrodermal activity, rest, and actigraphy data.
- Stanford Study looks at early disease detection using Empatica wristband
- Empatica AURA wearable can successfully detect flu and other respiratory infections
- Galvanic Skin Sensor technology on wearables is just getting started
EmbracePlus also enables the development and monitoring of digital biomarkers, the output of data reprocessed by algorithms.
The watch is also equipped with integrated PRO functionality making it a great choice for your clinical trials.
It supports direct integration of patient-reported outcomes, collecting questionnaires and notifications through watch input.
EmbracePlus also comes complete with a portable on-wrist charger, guaranteeing infinite battery life. This allows for continuous, unobtrusive data collection free of interruptions.
EmbracePlus has been developed with key partners, including HHS, USAMRDC, and the NASA-funded Translational Research Institute for Space Health. It is currently being rolled out for use with select clinical partners and will not be directly available to consumers.
Empatica CTO Simone Tognetti stated: “The EmbracePlus is the result of years of hard work from our team, culminating in a medical device that offers the best of Empatica’s technology, used in over 1,000 published papers: a compact and comfortable design with powerful sensors. We believe it will help in delivering our vision, to help millions of patients with new insights about their health and ultimately better care.”
Empatica’s smartwatches have been used in several studies, including Stanford University, to help study the early detection of respiratory infections.
The company’s Aura product recently won CE approval for use in the early detection of COVID-19.
Empatica’s research goes back to 2007 on a project led by Prof. Rosalind Picard, now Empatica’s chief scientist, at the MIT Media Lab.
Picard, who also co-founded Affectiva (a local company focusing on Emotion AI that raised more than $26 million), developed consumer-friendly wearables as part of a previous venture, Physiio International Inc.